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The Biological Disappearance Rate of Prothrombin, Factors VII' IX
and X from Plasma in Hypothyroidism, Hyperthyroidism, and
During Fever
From the Haematology Section ot' tbe Departrnent of Internal Medicine (Head: Prof. J. Mwldet,
M.D.), uniztersity Hospital, and. the Thrombosis Serrtice (Head: E. A. Loeliger, M.D.')' Leyden,
The Netberlands
E .  A .  L o e l i g e r ,  B .  v a n  d e r  E s c h ,  M i e k e  J .  M a t t e r n
a n d  H .  C .  H e m k e r
F .  K .  S C H A T T A U E R - V E R L A G  .  S T U T T G A R T
The disapp earartce rate of coagulation factors from plasma generally has
been determined in normal individuals and in patients suffering from congenital
coagulation factor deficiency, but otherwise being healthy. Litde is known
about the disappearan ce rate under altered metabolic conditions. During the
last few years we have collected data concerning the biological half-life of
Factors II, VII, IX and X in hypothyroidism, hyperthyroidism, and during
fever. The results seem worth publishing.
Patients
Fifteen normal individuals (members of the staff, average age about 30 years), 10 patients
with myxoedema'r, 5 patients with thyreotoxicosis'r-, 5 patients with elevated body temperatures,
and 6 "control" patients (patients without fever and with apparently normal thyroid function)
are included in this study. Pertinent data concerning the patients are given in Table 1,
Methods
Both normal individuals and patients were given a loading dose of 80-100 mg aceno-
coumarol (Sintrom "Geigy") between 9:00 p.m, and 2:00 a.m., fol lowed by one dai ly
dose of at least 40 mg until the end of the experiment; this high amount of a 4-hydroxycoumarin
derivative, approximately ten times the normal mean therapeutic dose, is considered to blod<
synthesis of Factors II, VII, IX and X, At the end of the experiment, the effect of aceno-
coumarol was counteracted, if necessary,by an oral dose of 
'10 
to 30 mg vitamin K, (Konakion
'Rodre"). In the "control" patients and in case of myxoedema, administration of the drug in
a therapeutic dose was contintred prophylactically.
'r \fle are irrdebted to Prof. A, Querido, M.D., and his staff, Department of Endocrinology
of the University Hospital, Leyden, for their invaluable cooperation.
Thrombos, Diathes, haemorrh.
da
d
> U
. : - Y  9 )
! ! ;  I
= d  > '
b F c  s
9 .  1
J E  X
X Hd d
; S
_ ;  > r
P . 9
o q g
O N
q 4 a a q \ n - q c - l
O N O I ' \ H O O - d i
\ 5
3
-X r e.t6 0
rf\o
o
€
6 < - 6 r n . +  a l
O : t O . . r H O N H N
i e
O O  \ o  O
is
O i ' \ @ N O
6 a i O O F \ O \ { - O O \  N . f N  < )
* o n o N 6 o * G l *  \ O n \ O  \ O|  |  |  |  |  I  I  |  |  |  +++  +
. - €
o d q t @ o \
* - o o 6 r l
6 l l l l l
=  q4 { .44
\ O N N N @
o 6 0 0 0
O O n 6 O O \ € @ n \ O  < - G l O
n n i i o @ @ < - 6 *  o \ o \ N\O \O 6 :f \O \O N 6'+ \O i i Gl
tr d. i-:.
: :  c v
E  g Y -
@ a @ € @
o o o 6 o
o i d +
F \ F \ N F \
c q o q q 9 , - . \ q 0 9 o 9 q q
\ O \ O \ O \ O N \ O \ O \ O \ O N
o o 6 6 0 6 6 0 6 S
i 9 ' 1 0 9 q
F \ \ O N \ O \ O
6 0 6 6 6
@
\o
bo
' :
. - :  3 . : ; * : i  t r  t r
' :  4 H H - E ' d  . .  . i { d r i  ! . 8 =i  E&ts  8# f .F .F . i ; . * t . i i . x  +r '>hh . -uS 'F3"
.  E i i . E  3 6 6 6 8 6 6 6 i i 6  h h H h H  h : ' i E ' i!  O ' t o ' t o ! ' i  6 " 6 . 6 . 6 . 4 n 6 . 4 6 . n  n X . 5 . 6 . 6 .  u P *  d *
' =  : c t r ' = t r  > r > ' x X x X x > . X X  X X > ' > . X  : . i . . : < j
a
6
$ 6 6 \ O t o ' { - ' + c . l  6  a l O \ € ' $ c )  6 : f  O \ n n
r n \ O \ O 6 o N t f  t \ O o  6 \ O + € h  N N $ \ f C . . |O  O \ \ O i N N6  N \ O \ O \ O r O
X
o q q q q q q q q q q  E  g q q q  q q  E  E qE  E o *
o
F
O \ O \ c | O \ o r . O . @ q  i H N e { N O N O N i  i i H i O  N N i O O
n h € n n h 6 6 € \O \O \O \O € \O \O \O \O \O \O \O \O \O \O \O \O \O \O\ \ \ \ \ \ \ >  \ \ \  \ \ \ \ \  \ \ \ \ \6 F \ O @ : @ i ! | l  N N i € + i N { - € N  @ € h O O \  t N O n 6
i 6 6 o ! - O \ O o  n O  \ O n < - O < - O \ O  N 6 6 @ i  h $ + 1 . \ hd N  6 O C { N 6  C . l O  n G l i . { -  { - O  i O  c ) \ O C . t h @
N \ O  i N
O . : . r , * , * . H  O ' i  A  O  O  O  o  O  O  O  O  O  O  O  O , i  O  . i . r
o
E
d
d
d
T" . l+o.i***i  *T* 4q :
.drsN ?i;: i l i++i : ;* ? iY, ;
t  E+ ' i : €  >d i?u r i i c i €?  ; - , c i c /T  j f  c i g<
-a Ci ,-,-F t ' i  d € > E '- '- '-t 
"-Ci < +-.,r; E '-C.l '--rt l
ii .6
€ 
'El
E L I
o i 9
> P? a
a F
o i
o  . i
s '6
'o !?
a - Y
- h o
9 ? c
i Y
, : E
A C B
- ^ o
F..9 0
o . l
\ O l  I
- , H  :
* ' E  :
o d x
5 5 X
. c o
1 4  o  . .
a.o t
o :'1 L:
uo'= H
' =  x "
r.r '0
E 9
' ' u
ti 'E
i d
x i j
- *
> ^ .
o D o
i o
o : ?
_ 6 d
J O
F F
Five ml blood samples were taken through a meticulous venepuncture using a polished
stainless-steel needle directly into a plastic tube containing 0.1 ml sodium citrate 0.55 mol., at
the intervals.indicated in the Figures. The blood was centrifuged at 23Q0 r.p.m. for 30 minutes
in order to obtain platelet-poor plasma. Plasma was handled and stored in carefully siliconized
glassware.
Analysis of coagulation was usually carried out within two hours, and exceptionally as
much as six hours after venepuncture. All coagulation tests were performed in ordinary
glassware, preheated to 37o C in a warerbath. For the measurement of the "prothrombin' time
we used the procedure described originally by Quick (10). Brain thromboplastin of human origin
was prepared according to Owren (9) and stored in small portions ^t - 25o C. The normal
"prothrombin" time value was 15.1 -f 0.7 seconds.
The activity of Factors II, VII, IX, and X was determined by means of the one-stage proce-
dure as described by us (6). The substrate plasma for the determination of Factors VII and IX
was collected from patients with congenital coagulation factor deficiency, that for the deter-
mination of Factors II and X s/as artificially prepared. The large normal range found for
Factors II and X in "control" patients (Fig. 2 and 4) is due to large differences in activity of
the different batches of the substrate plasma used. In the Factor IX test, BaSOu-adsorbed oxal-
ated plasma was added to the incubation mixture (6).
In the evaluation of the results of Factor IX. disappearance rate statistical analysis was
applied't.
Results
After oral intake of the coumarin drug acenocoumarin) some hours elapse
before the activity of Factors II, VII, IX and X starts to decrease and prolon-
gation of the "prothrombin" time commences. This "silent period", which nor-
mally lasts 4-8 hours, appears to be shorter in thyreotoxicosis and fever (shor-
test value 2.5 hours), whereas in myxoedema the beginning of the reaction may
occur as late as 15 hours after oral intake. The individual data can be estimated
from Figure s l-.4.
The prolongation of the coagulation times appears to take place exponentially
(2); straight lines are obtained when the logarithm of the coagulation time is
plotted against observation time (Fig. 1, 2, 3, and 4). The tangent of the angle
between these lines and the X-axis is the parameter for the prolongation rate.
The tangent values for coagulation times ("prothrombin" time as well as coa-
gulation time found in the specific coagulation factor assay system) found in
:normal individuals are taken as reference for changes in the disappearance rate
.of the coagulation factors in patients. The degree of change is assessed by calcu-
lating the ratio, patient's value: normal value.
'F We are indebted to Dr. E. F. Drion, Head of the Statistics Department T. N. O., The
llague, for his invaluable help with the statistical analysis.
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F i g. 1 : Prolongation rate of the "prothrombin" dme after blocking synthesis of Factors
II, VII, IX and X in normal 
"""$?,:";::l1ol" patients, and patients with different
Abscissar observation time (hrs.); ordinate: "prothrombin" time (sec.), logarithmic scale
Figure 1 demonstrates the prolongation rate of the "prothrombin" time. In
thyreotoxicosis and patients with fever the. rate is clearly increased, whereas
in myxoedema it is decreased. The average acceleration in thyreotoxicosis and
fever is L.3l and 1..77 times normal, respectivelyi average doubling of the
"prothrombin" time takes place after 18 and 1,3.5 hours, respectively, instead
of the normal 24 hours. The highest rate is found in a case of sarcoma (i.1054162)
with remittent temperatures of up to 40o C; it appears to be about three times
normal (Fig. 1, dotted line), In myxoedema the increase of the "prothrombin"
time is retarded on the average to 0.59; doubling of the "prothrombin" time
takes place only after about'4L hours, on the ayerage, instead of the normal
24 hours. The longest time required for doubling is 50 hours, whidr correspolrds
with a decrease of the prolongation rate to 0.48 times the normal value.'
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Fig, 2: Prolongation rate of the
coagulation times found in the
Factor Il-assay system.after block-
ing synthesis of Factors II, VII,
IX and X in "control" patients
and patients with different clinicdl
conditions
Abscissa: observation time (hrs.);
ordinate: coagulation time (sec.),
logarithmic scale
F i g. 3 : Prolongation rate of the
coagulation times found in the
Factor Vll-assay system after
blocking synthesis of Factors II,
VII, IX and X in ocontrol"
patients and patients with different
. clinical conditions.
Abscissa: observation time (hrs.);
ordinate: coagulation time (sec.),
logarithmic scale
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Frorn Figures 2,3 and 4 it can be seen that, regarding the disappearance
rate of Factors II, VII and X, similar conclusions are justified. The degree of
acceleration and retardation of the prolongation (c. q. disappearance) rarc of
the coagulation times (c. q. factors) is calculated by means of the best-fitting
regression curves (solid and dotted lines). As far as Factor VII is concerned,
the conclusions are evident in all instances, but for Factors II and X only the
retardation of the disappearance rate in patients with myxoedema is conclusive;
an acceleration seems probable in thyreotoxicosis and during fever; for a more
significant result concerning the acceleration of the disappearance rate of Fac-
tors II and X in thyreotoxicosis and during fever a longer observation time is
needed; a significant acceleration in case of fever has, however, already been
demonstrated by one of us (2).
0 2 4
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FoctorX
Fig.4: Prolongation rate of the coagulation rr-., ,oorrdll"Factor X-assay sysxem
after blod<ing synthesis of Factors II, VII, IX and X in "control" patien* and patients
with different clinical conditions.
Abscissa: observa.tion time (hrs.); ordinate: coagulation time (sec.), logarithmic scale
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Fig. 5: Disappearance rate of Factor IX in terms of biological half-time in a hypothyroid
female patient, aged 44 years (nr. e 44163). The half-time values were obtained by means
of regression analysis of the Factor IX-activities, found on four successive-days. Sixty
hours (with a 95a/o confidence interval of 48-72 hours) is the result obtained when
the low Factor IX-activity, found on the second day, is not taken into accounr; 72 hours
is the result when no value is omitted
24 48
Observotion time (hrs)
F i g. 6 : Disappearance rate of Factor IX in terms of biological half-time (plus 950/o
confidence interval) in a male patient, aged 33 years, with continuously strongly elevated
body temperature (about 39o C), due to an untreated sarcoma (lab. nr. 311/63). The figures
are the result of statistical analysis of the Factor lX-activity, found at the beginning and
at the end of the experiment. The decrease of the Factor IX-activity was assumed to have
started between 2.5 and 3 hours after oral intake of the loading dose acqpocournarin,
.together with the prolongation of the "prothrombin" time
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'Ihe Factor IX activity could not be studied systematically, for tedrnical
reasons. Retardation of the disappearance rate of Factor IX was demonstrated
in only one patient, suffering from myxoedema, in whom the prolongation rate
of the "prothrombin" time was 0.49 times normal (Fig. 5).
The acceleration of the disappearance rare of Facror IX was evident in
another patient with fever, in whom the prolongation rate of the "prothrombin"
time was 2.4 times normal (Fig. 6).
The results are presented comprehensively in Table 2. The degree of retarda-
tion and acceleration of the disappearance rate appears to be quite similar
whether expressed in terms of prolongation rate of the "prothrombin" time or
in terms of the prolongation rate of the coagulation times obtained in the specific
one-stage assay.
Tab le2zTab le2 isasynops iso f theresu l tsob ta ined.Thepro longat ionra teo f thecoagu la t ion
times found in patients is cornpared with those in normal controls and/or "control" patients.
The results are presented as ratiq patient's prolongation rate: normal prolongation rate.
Tte figures given under "p. t." ("prothrornbin" time), are more accurate than those under "II",
"VII", and "X", because the number of "prothrombin" times has been higher and also the error
of determination is considerably lower for the "prothrombin" times than for coagulation times
obtained from the assay of the three coagulation factors separately. The fgures given under "II".
"VII", and "X" do not differ significantly from those given under "p. t."
Average prolongation rate of coagulation times
Normal controls
"Control" patients
Myxoedema
Thyreotoxicosis
Fever
X
1 n1 n
0.61 0.65
Discussion
Synthesis of prothrombin Factors VII, IX and X is supposed to be blocked
almost completely after oral intake of a loading dose of 8O-1OO mg (20-25
tablets) followed by one daily dose of at least 40 mg (10 tablets) of the 4-hy-
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droxycoirmarin derivative acenocoumarol (Sintrom "Geigy"). Evidence for
blocked synthesis during similar posology *ill be given elsewh ere (2).
It takes about. 2.5-15 hours before prolongation of the "prothrombin" rime
(c. q. decrease of the coagulation factor activity) begins; the shortest intervals
("silent period") between intake of the drug and reaction of the "prorhrombin,,
time are found in fever and hyperthyroidism, the longest in myxoedema. Four
to eight hours seems to be the normal range.
The prolongation rate of the "prothrombin" time is exponential up to values
of about four times normal (2). The mean normal "doubling time,, is 24 hours.
In myxoedema the mean is much longer, about 41. hours, the longest ..doubling
time" being approximately 50 hours, whereas in hyperthyroidism and fever a
marked increase of the prolongation rate is observed. The patients with thyreo-
toxicosis and fever (the latter having a mean body tempe rature of about
38.20 c) show a mean accelerarion of t.lt and 1.77 rimes, respectively. The
shortest "doubling time" was about 8 hours, which corresponds wiih a proio.rgur-
ion rate of about thrice normal; this concerned a patient with high body temper-
ature due to a necrotizing malignant lymphoma. Since the longest ..doubling tile"
in a case of myxoedema was about 50 hours, the fastest and slowest prolongation
rate of the "prothrombin" time differ by a factor of at least 6. It is most inter-
esting in this respect that the shortest and longest ..silent period,, also differ by a
{actor of about 6.
The prolongation rate of the Factor Vll-coagulation time shows a clear-cut
correspondence with the prolongation rate of the "prothrombin,, time in all
instances. The values for Factors II and X behave similarly, the correlation being
most evident in myxoedema.
_ .considering the prolongation rate of coagulation times as parameter of the
biological disappearance rate of coagulation factors, the latter )pp" r, to be far
from constantl decrease to about 0.5 times normal and increase up to three times
the normal rate can occur..
Alterations in the biological disappe arance rate under pathological conditions
occur in other coagulation factors besides Facrors II, VII, and X. Concerning
Factor IX we think an increased disappearance rare during fever has been
proven by studies made during substitution therapy in haemophilia B (5) and is
further demonstrated by the data in Fig. 6; a decrease of th" Factor IX-dis-
appearance rate was found in one of our myxoedema cases (Fig. 5). Factor VIII
appears to be more rapidly consumed in patients after surgical treatment (g). The
disappearance rate of fibrinogen was observed to be increased in a case of
complete liver dystrophy accompanied by elevated body temperatures (4); on
the other hand, significant retardation of consumption has been demonstrated in
myxoedema (3). Serum albumin, in severe illness, apPears to decay considerably
faster than is normally rhe case (1). In fact, such changes seem to be a non-
specific phenomenon inherent in protein metabolism itself'' 
Th.'."nre-of the alterations-in metabolic activity of coagulation factors in
myxoedema, thyreotoxicosis, and fever is as yet unknown' Thyroxin should be
co.rsidered as one of the possible pathogenetic agents. Animal experiments may
teadr us more (7).
The practical consequences of large differences in the metabolic decay of the
.org,rlution factors .orr.",,,"d i" this study are at 1911 twofold' Firstly' in
coumarin treatment, therapeutic hypocoagulability will be readred in patients
with high fevers up to thr:ee times larfiei that in afebrile patients' whereas in
hypothyroidism it will take much longer than is normally the case. This is of
,i".irt i*porru.r." in relation to co-bined heparin/coumarin treatment: heparin
must be administered until the activity of Factors IX and X is between 10 and
25o/o f normal. Hence, in patients *ith ,ror-ul metabolic activity' the minimal
;;r;r; of heparin therapy will be 4_5 days; hypothyroid patients musr be
t,reatedfo, -or" than aweet; with elevated body temperatures, however, 2 days
of heparin will often be sufficient. secondly, for substitution therapy in christ-
,,,u, iir.ur", the minimum amount of Factor IX needed for safe haemostasis, i' e'
for the mainrenance of a 25olo level, will vary gready with changes in the
prri"rrr,, metabolic acti:Vity, up to three times the amount calculated from the
normal disappearance tate of Factor IX will be needed. If the aetiology of the
accelerated isappearance of coagulation factors were known, specific inh-ibitors
could be used to drastically ,i-p[ry substitution thetapy in christmas disease,
and in other coagulation factor deficiencies'
SummarY
The biological disappearance fate of coagulation factors II, vII, IX and X
frorn plasma"is decrea's"d ir, -y"oedema and'increased in thyreotoxicosis' In
patienis with elevated body temperatures, an increase of up to three times the
normal rate was observed. The ciinical implications of these findings are briefly
discussed.
R6sum6
La vitesse de disparition des facteurs de coagulation II, VII, IX et X est
diminu6e 
"r, 
.", d'hyiothyr6oidie et acc6l6r6e n cas d'hyperthyr6oidie' La vitesse
p"", err" acc1l;r6e'1.rrq,r;l trois fois la normale diez des malades fi6vreux' Les
276
cmiquences de ces rdsultats sont de grande importance dans le traitement aux
enticoagulants er pendant la substitution chez I'hdmophile par du plasma frais
ar des prdparations concentr6es de facteurs de coagulation.
Zusammenfassung
Die biologische Halbwertszeit der Gerinnungsfaktoren II, vII, IX und X ist
im Blut von Myxcidempatienren vermindert und im Falle von Hyperthyreoidie
-erhciht. Bei fieberhaften Zustdnden kann der dreifache lflert der Norm erreicht
werden. Die Folgerungen dieser Befunde ftir die Klinik werden kurz diskutiert.
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